

Advances in Medical Epigenetics: A Review Article

Shaymaa Omar Mohammed

College of Biomedical Engineering, University of Technology, Baghdad, IRAQ

Corresponding Author: shaymaa.o.mohammed@uotechnology.edu.iq



www.sjmars.com || Vol. 5 No. 5 (2026): October Issue

Date of Submission: 19-09-2026

Date of Acceptance: 06-10-2026

Date of Publication: 14-10-2026

ABSTRACT

Epigenetics has emerged as an important field in modern medicine, providing new insights into the regulation of gene expression and the development, progression, diagnosis, and treatment of human diseases. Unlike genetic mutations, epigenetic modifications can alter gene activity without changing the underlying DNA sequence. This review discusses recent advances in medical epigenetics, with particular emphasis on three major regulatory mechanisms: DNA methylation, histone modifications, and non-coding RNAs. These mechanisms interact with genetic, environmental, and cellular factors to regulate gene expression and may contribute to disease development across multiple biological systems. The review highlights the influence of environmental exposures, nutrition, lifestyle, stress, and early-life experiences on epigenetic regulation and their potential long-term effects on health. The role of epigenetic alterations in systemic disorders, cancer, cardiovascular and respiratory diseases, neurological conditions, immune-related disorders, and other multisystem diseases is also examined. Furthermore, advances in epigenetic biomarkers and bioinformatics, including machine-learning approaches, are discussed for their potential applications in disease diagnosis, prognosis, and precision medicine. Particular attention is given to pharmacological and therapeutic strategies targeting epigenetic mechanisms, including DNA methylation inhibitors and histone-modifying agents. Although challenges remain regarding treatment specificity, safety, toxicity, and the complex interaction between genetic and environmental factors, continuing advances in epigenomic technologies and personalized medicine are expanding the clinical potential of medical epigenetics. Overall, epigenetic research represents a promising approach for developing individualized strategies for disease prediction, prevention, diagnosis, and treatment.

Keywords- Medical epigenetics; DNA methylation; histone modifications; non-coding RNA; epigenetic biomarkers; bioinformatics; precision medicine; epigenetic therapy; gene expression.

I. INTRODUCTION

Biochemical changes to DNA, proteins bound to it, or RNA are involved in epigenetic processes; these changes do not change the DNA sequence itself but impact gene expression levels. In medicine, epigenetics is vital because it opens up new possibilities for managing diseases at every stage, from diagnosis to therapy and beyond, including prognosis [1]. Epigenetic processes impact almost every bodily system. Epigenetic processes often have an impact on multiple biological systems [2]. Among the many diseases and disorders linked to epigenetics are those involving DNA methylation, histone changes, and noncoding RNA. Epigenetic anomalies manifest in a wide variety of pathogenic features, and all of these routes may affect gene expression.

II. BASIC PRINCIPLES OF EPIGENETICS

Among the key epigenetic processes, DNA methylation has received the most attention from researchers. It has been a long-standing foundation for our understanding of the role of epigenetics in various biological processes, including X chromosome inactivation and the inheritance of epigenetic information during mitosis, among many others[3]. In the

early days of the field of epigenetics, studies on DNA methylation were crucial in paving the way for the realization that even minor changes to DNA can have significant effects on health [4]. The byproduct of DNA methyltransferases (DNMTs)—which catalyze DNA methylation—is 5-methylcytosine (5mC), which may undergo further modifications and causes several changes in biology [6]. To create 5-hydroxymethylcytosine (5hmC), the ten-eleven translocatedioxygenases (TET) enzymes may alter 5mC[5]. From there, they can generate 5-formylcytosine and 5-carboxylcytosine. After DNA repair procedures have corrected the damage, an enzymatic conversion of 5mC to cytosine is a crucial outcome. Enzymatic processes allow for the incorporation and removal of DNA methylation from the genome[6].

In medical diseases where changes in gene expression are linked to differences in DNA methylation, the reversibility of DNA methylation might have several ramifications. When a result of enzymatic activity, histones also undergo reversible alterations in their modifications as disease begins and progresses. For instance, histone acetyltransferases (HATs) often cause an upregulation of gene expression by attaching acetyl moieties to histones' N-terminal tails. The histone deacetylases (HDACs), which are responsible for removing acetyl groups from histones, play a crucial role. Cognitive decline is a hallmark of neurodegenerative diseases, and HDAC inhibitors may represent an important therapeutic target in this regard [7]. There is considerable hope that noncoding RNAs (ncRNAs), the third major player in human cell epigenetic alterations, may impact medical diagnosis, therapy, and prognosis [8]. Many medical diseases have a strong epigenetic component. When these three routes for mediating epigenetic alterations are combined, they provide a high proportion of epigenetic control over gene expression. More importantly, these epigenetic modifiers generally work together in a cross-talk process rather than acting independently. Intraepigenetic interactions open up a world of possibilities, including the possibility that DNA methylation and histone modifications work together to regulate gene expression[9]. It is not uncommon for these epigenetic pathways to interact with transcription factors and other key regulators of gene expression[10].

III. SUMMARY OF KEY EPIGENETIC MECHANISMS

The following table outlines the three primary epigenetic mechanisms, their key enzymes, functional impact on gene expression, and associated medical conditions:

Epigenetic Mechanism	Key Enzymes / Mediators	Impact on Gene Expression	Associated Medical Conditions
DNA Methylation	DNMTs, TET enzymes	Repression or regulation of gene transcription	Cancers, neurological disorders, aging
Histone Modifications	HATs, HDACs, HMTs	Upregulation (acetylation) or repression (methylation)	Neurodegenerative diseases, cancer, inflammation
Noncoding RNAs (ncRNAs)	miRNAs, lncRNAs, siRNAs	Post-transcriptional silencing or translation inhibition	Cardiovascular diseases, autoimmune disorders, tumors

IV. GENERAL MEDICAL ASPECTS OF EPIGENETICS

A significant knowledge gap remains regarding the temporal aspects of epigenetic alterations that occur throughout a person's lifespan, despite a considerable understanding of epigenetics and its medical applications. Epigenetic changes during formative years may have far-reaching effects on adult health, according to available research[11]. Epigenetic abnormalities may contribute to disease development in later life, and exposure to environmental stressors is a significant variable that can lead to epigenetic alterations in early life. Ecological circumstances, one's diet, and the amount and quality of physical activity one engages in can all impact epigenetic modifications, which can have either positive or negative effects on health, depending on the type of lifestyle change[12]. Together, health promotion and illness prevention are cornerstones of medical treatment; they will drastically cut healthcare expenditures and human suffering caused by diseases.[13]. Some medically related problems may be preventable or at least slowed in their course if we "get ahead of the curve" and concentrate on the effects of epigenetic disease prevention. There are precise temporal frames in which environmental exposures to air, food, and personal care products might affect epigenetic pathways[14]. Pollution, allergies, chemicals, and food are all examples of environmental variables. Although environmental influences on epigenetic disease characteristics are a traditional aspect of epigenetics, they have received relatively little attention, despite the rapid growth of the field of epigenetics. Significant new findings in this vital area of medical epigenetics will undoubtedly continue to emerge. In fact, epigenetic changes influence the way early life experiences impact behaviour. Changes in behaviour may result from epigenetic marker modifications caused by stress and cortisol, which in turn may affect gene expression[15].

For instance, glucocorticoid-related behavioural abnormalities have been linked to genes involved in the hypothalamic-pituitary-adrenal axis, and glucocorticoids may alter epigenetic processes, including DNA methylation and histone modifications, which in turn affect genes that code for neurotransmitters. Some mental disorders and odd behaviours

may be brought on by or exacerbated by these changes. Researchers have been perplexed by the age-old nature vs. nurture debate over the role of these crucial factors in the genesis of illness for almost as long as this knowledge has existed[16]. The study of twins, particularly monozygotic twins, has shown that environmental factors influence the epigenetic machinery and that phenotypic variability increases with age. Twin studies have great potential in revealing the epigenetic consequences of complicated traits and many diseases, according to an intriguing survey of Joel Eissenberg.

However, a major obstacle to this endeavour will be determining how to fully address age-related "epigenetic drift fully" and identifying which of the epigenetic changes that differ in twins as they age are actual causes of illness and which are merely pathological effects. This is a further fundamental challenge in medicine, regarding the relative importance of genetics and environmental factors, or cause and effect. Twin studies will undoubtedly shed light on the importance of epigenetics in healthcare. Although it's still in its infancy, I believe this field holds tremendous promise for addressing many of the key questions about medical epigenetics. Improving our capacity to identify illnesses and predict their consequences more accurately is just as important as deepening our knowledge of the concepts of epigenetics in medicine. Epigenetic biomarkers, which may be used for the diagnosis and prognosis of various illnesses, including cancer, are being developed thanks to advances in medical epigenetics. There are promising avenues for creating biomarkers for early diagnosis and, potentially, disease prevention that may be uncovered through the identification of epigenetic alterations in medical illnesses. Not only are histone modifications and DNA methylation important epigenetic indicators, but so are noncoding RNAs. For example, at different stages of a disease, several of these epigenetic biomarkers significantly enhance the ability to predict a patient's therapy outcome[17].

V. EPIGENETICS OF SYSTEMIC DISORDERS

Because epigenetic pathways can significantly influence gene expression, it is not unexpected that epigenetic aberrations impact nearly every biological system, ranging from skin disorders to gastrointestinal problems to cardiovascular diseases. It is now understood that epigenetic alterations can impact both the initiation and progression of immune-based disorders. New evidence suggests that immune cells may store information about previous infections in the form of changed epigenetic marks, a "memory" of sorts. Exciting possibilities exist for improved precision medicine for diseases involving the immune system as a result of this novel approach. Epigenetic abnormalities are associated with a variety of respiratory disorders, including COPD, asthma, idiopathic pulmonary fibrosis, and other interstitial lung diseases. The pulmonary system is especially vulnerable to these aberrations. Furthermore, epigenetic alterations have the potential to personalize the epigenome and provide biomarkers for disorders affecting the cardiovascular system. There may be hope for epigenetic-modifying medications as a means of reducing the risk of cardiovascular disease, which includes hypertension, smoking, and obesity[18].

In addition to epigenetic abnormalities in these systems, environmental variables such as nutrition can influence the microbiome, which in turn can be influenced by epigenetic factors that interact with genetic, dietary, and microbial signals. Epigenetics also underpins several musculoskeletal disorders. Possible therapies for epigenetic-based skin problems include those related to ageing skin, skin cancer, and immunologic skin infections; epigenetic changes may also play a role in the development of skin cancer[19].


VI. MULTISYSTEM MEDICAL EPIGENETICS

Many of the epigenetic pathways that contribute to illness may manifest as abnormalities affecting multiple systems in the body. As shown before, environmental insults inflicted at an early age may significantly alter the functioning of several systems throughout infancy and maturity. Crucial factors include the impact of epigenetics on birth weight and the development of childhood obesity. Taking into consideration a variety of aspects, such as the effect of epigenetics on environmental exposures, birth weight, and pregnancy histories, multigenerational paediatrics is a new field that is showing potential. Epigenetic changes in both the host and bacterial pathogens influence the aggressiveness and characteristics of many infectious diseases, and infections may spread to other parts of the body (as mentioned in [20]) Undoubtedly, tumor genesis stands out from the others. The fact that it usually affects more than one system in the body is one way in which it is similar to other epigenetic diseases. The role of epigenetics in cancer is well-established. Historically, epigenetic medicines have had limited bioavailability to solid tumors, making it difficult to treat solid malignant tumors in many systems such as the lungs, liver, and breast.

Nevertheless, significant progress has been made in the early detection of cancer through the use of epigenetic biomarkers and their prognostic potential. Additionally, treatment, particularly combination therapeutic approaches, is showing promise for various solid tumours. Acute myeloid leukaemia is a stunning example of how epigenetic alterations are essential in haematological malignancies, which also include solid tumors. Despite the lack of extensive epigenetic-based treatments for acute myeloid leukaemia, numerous approaches are currently under development that target histone methyltransferases (HMTs), microRNAs (miRNAs), and histone deacetylase (HDAC) inhibitors[21].

VII. MEDICAL EPIGENETICS PATHWAY & ENVIRONMENTAL INTERACTION

The structural flowchart below outlines how external factors and lifestyle elements drive epigenetic alterations leading to systemic clinical manifestations:



Bioinformatics of epigenetic medicine

The field of bioinformatics is rapidly establishing itself as a crucial component of epigenetics and its medical applications. Most importantly, machine learning—which comprises methods by which algorithmic computers can "learn" from and adjust to data to improve performance and precision—can analyze epigenetic events to predict illnesses. Improving phenotypic prediction for more precise diagnosis and predicting the clinical course of disease would be a fascinating contribution to the field of epigenetics. DNA methylation has significant potential in the field of machine learning, particularly when applied to complex diseases. The application of machine learning in epigenetic disorders appears to hold great promise. It has the potential to revolutionise the management of illnesses based on epigenetic principles[22].

Pharmacology of epigenetics

The relative safety of epigenetic agents is a significant concern in medical epigenetics, especially in light of the discovery of several novel epigenetic drugs and the ubiquitous nature of epigenetics. Selective targeting of novel medications with minimal off-target effects is of the utmost importance. Medical epigenetics will increasingly rely on clinical trials and comprehensive toxicity investigations of newly created epigenetic therapeutics. Building on epigenetic analysis as a foundation, we aim to develop novel and tailored drug treatment applications. When these factors are taken into account, it becomes apparent that pharmacoeugenetics is a rapidly expanding field. Suppose medical epigenetics is to achieve its full potential. In that case, the next generation of drugs that target epigenetic-based diseases must be developed[23].

Therapeutic epigenetics

Identifying ways to modify or correct epigenetic aberrations that contribute to disease is a fundamental objective of medical epigenetics. The use of inhibitors of DNA methylation is a rapidly growing and important field of therapeutic epigenetics. Cancer cells may have their tumour suppressor genes demethylated and reactivated with medications like azacitidine and decitabine. Due to their increased bioavailability, these demethylating medications have proven to be the most effective in treating hematologic diseases, including acute myeloid leukaemia and myelodysplastic syndromes, whether used alone or in combination. The potential of demethylating medications to treat solid tumours, in part through combinatorial approaches, and their potential use in treating diseases other than cancer are the current focus of much research and development activity[24].

Medical epigenetics: Prospects

Some external signals influence the epigenetic apparatus, including dietary habits, environmental conditions, and psychological variables that can trigger stress signals, which in turn can lead to epigenetically based disease processes. Many subsequent studies will likely aim to clarify the role of stress in medical epigenetics. New epigenetic codes, such as the "histone code," and the development of advanced methods for epigenomic research have also opened up exciting and crucial avenues for significant progress in medical epigenetics. There is a strong likelihood that the US Food and Drug Administration (FDA) will approve many more epigenetic-modifying medicines, and the FDA has already authorised several novel epigenetic pharmaceuticals. A vital tool for medical treatment, reference epigenome mapping is an ongoing effort of the International Human Epigenome Consortium. About applications to precision epigenetic medicine, as well as for use in diagnosis, prognosis, and treatment, this new data will be indispensable[25].

VIII. CONCLUSION

Exciting new developments in epigenetics are paving the way for patient care approaches that were previously unfeasible. When it comes to epigenetic processes, environmental factors have a disproportionate impact. As our planet

undergoes massive ecological change, we must learn more about the role of epigenetic processes and abnormalities in the development of many diseases. It wasn't long ago that cancer was the only illness thought to have an epigenetic component, and epigenetic treatment was almost limited to just one condition. Given that epigenetic processes impact nearly every bodily system and that these mechanisms manifest across multiple systems, epigenetic treatment may be beneficial in addressing illnesses that affect more than one system simultaneously. Recent scientific progress in epigenetic medical therapeutics has shown promise in treating a variety of diseases and conditions by altering gene expression. These include, but are not limited to, neurological disorders, cancer, metabolic disorders, pain, infectious diseases, and paediatrics. Due to the rapid development of new methods for individualised epigenetic diagnosis and treatment, epigenetic therapy is quickly becoming a crucial component of precision medicine.

REFERENCES

- [1] Monte-Serrano, E., Morejón-García, P., Campillo-Marcos, I., et al. (2023). The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase. *Epigenetics & Chromatin*, 16, 18. <https://doi.org/10.1186/s13072-023-00494-7>
- [2] Oosterhof, M. M., Coussement, L., van Pijkeren, A., et al. (2024). Changes in histone lysine acetylation, but not DNA methylation during facultative hibernation in Syrian hamster liver. *Epigenetics Communications*, 4, 1. <https://doi.org/10.1186/s43682-023-00024-2>
- [3] Reers, A. B., Bautista, R., McLellan, J., et al. (2023). Histone modification analysis reveals common regulators of gene expression in liver and blood stage merozoites of *Plasmodium* parasites. *Epigenetics & Chromatin*, 16, 25. <https://doi.org/10.1186/s13072-023-00500-y>
- [4] Natu, A., Verma, T., Khade, B., et al. (2024). Histone acetylation: a key determinant of acquired cisplatin resistance in cancer. *Clinical Epigenetics*, 16, 8. <https://doi.org/10.1186/s13148-023-01615-5>
- [5] Liang, B., Wang, Y., Xu, J., et al. (2023). Unlocking the potential of targeting histone-modifying enzymes for treating IBD and CRC. *Clinical Epigenetics*, 15, 146. <https://doi.org/10.1186/s13148-023-01562-1>
- [6] Wang, Z., Liu, Z., Lv, M., et al. (2025). Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation. *Clinical Epigenetics*, 17, 30. <https://doi.org/10.1186/s13148-025-01838-8>
- [7] Ji, Y., Chen, Z., & Cai, J. (2025). Roles and mechanisms of histone methylation in vascular aging and related diseases. *Clinical Epigenetics*, 17, 35. <https://doi.org/10.1186/s13148-025-01842-y>
- [8] Qin, Y., Yang, P., He, W., et al. (2024). Novel histone post-translational modifications in Alzheimer's disease: current advances and implications. *Clinical Epigenetics*, 16, 39. <https://doi.org/10.1186/s13148-024-01650-w>
- [9] Zhang, L., Xia, C., Yang, Y., et al. (2023). DNA methylation and histone post-translational modifications in atherosclerosis and a novel perspective for epigenetic therapy. *Cell Communication and Signaling*, 21, 344. <https://doi.org/10.1186/s12964-023-01298-8>
- [10] Waterfield, S., Yousefi, P., & Suderman, M. (2024). DNA methylation models of protein abundance across the lifecourse. *Clinical Epigenetics*, 16, 189. <https://doi.org/10.1186/s13148-024-01802-y>
- [11] Fang, F., Zhou, L., Perng, W., et al. (2023). Evaluation of pediatric epigenetic clocks across multiple tissues. *Clinical Epigenetics*, 15, 142. <https://doi.org/10.1186/s13148-023-01552-3>
- [12] Neto, S., Reis, A., Pinheiro, M., et al. (2024). Unveiling the molecular landscape of cognitive aging: insights from polygenic risk scores, DNA methylation, and gene expression. *Human Genomics*, 18, 75. <https://doi.org/10.1186/s40246-024-00640-6>
- [13] Yang, S., Chen, L., Lin, M., Shen, C., & Reheman, A. (2025). Histone Modifications as Individual-Specific Epigenetic Regulators: Opportunities for Forensic Genetics and Postmortem Analysis. *Genes*, 16(8), 940. <https://doi.org/10.3390/genes16080940>
- [14] Lavoro, A., Falzone, L., Tomasello, B. M. R., Conti, G. N., Libra, M., & Candido, S. (2025). Recent advances on gene-related DNA methylation in cancer: technologies, diagnosis, prognosis, and epigenetic drugs. *Clinical Epigenetics*, 17, 184. <https://doi.org/10.1186/s13148-025-01884-2>
- [15] Dai, W., et al. (2024). Epigenetics-targeted drugs: current paradigms and future directions. *Signal Transduction and Targeted Therapy*, 9, 389. <https://doi.org/10.1038/s41392-024-02039-0>
- [16] Deshmukh, M. G., et al. (2025). DNA methylation in melanoma immunotherapy. *Clinical Epigenetics*, 17, 65. <https://doi.org/10.1186/s13148-025-01865-5>
- [17] Song, J., et al. (2025). Targeting epigenetic regulators as a promising avenue to overcome therapeutic resistance in cancer therapy. *Signal Transduction and Targeted Therapy*, 10, Article. <https://doi.org/10.1038/s41392-025-02266-z>
- [18] Song, P., et al. (2025). New generation of clinical epigenetics analysis and diagnosis. *Diagnostics*, 15(12), 1539. <https://doi.org/10.3390/diagnostics15121539>
- [19] Li, S., et al. (2024). Research hotspots and trends of epigenetic therapy in cancer: a bibliometric analysis. *Frontiers in Pharmacology*, 15, 1465954. <https://doi.org/10.3389/fphar.2024.1465954>

-
- [20] Rossi, A., et al. (2024). Progresses and pitfalls of epigenetics in solid tumors: combining precision medicine with epigenetic drugs. *International Journal of Molecular Sciences*, 25(21), 11740. <https://doi.org/10.3390/ijms252111740>
- [21] Tigu, A. B., Ivancuta, A., Uhl, A., et al. (2025). Epigenetic Therapies in Melanoma — Targeting DNA Methylation and Histone Modification. *Biomedicines*, 13(5), 1188. <https://doi.org/10.3390/biomedicines13051188>
- [22] Epigenetic modifications in cardiac fibrosis: recent evidence of new roles and therapeutic prospects. (2025). *Frontiers in Molecular Biosciences*. <https://doi.org/10.3389/fmolb.2025.1583446>
- [23] Weaver, I. C., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., ... & Meaney, M. J. (2004). Epigenetic programming by maternal behavior. *Nature Neuroscience*, 7(8), 847–854. <https://doi.org/10.1038/nn1276>.
- [24] Mill, J., & Heijmans, B. T. (2013). From promises to practical strategies in epigenetic epidemiology. *Nature Reviews Genetics*, 14(8), 585–594. <https://doi.org/10.1038/nrg3405>
- [25] Dawson, M. A., & Kouzarides, T. (2012). Cancer epigenetics: From mechanism to therapy. *Cell*, 150(1),